InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Short Interest Down 17.0% in April
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 4,110,000 shares, a drop of 17.0% from the March 31st total of 4,950,000 shares. Based on an average trading volume of 3,890,000 shares, the days-to-cover ratio is presently 1.1 days.
An institutional investor recently bought a new position in InVivo Therapeutics stock. Renaissance Technologies LLC bought a new stake in InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 111,474 shares of the biotechnology company’s stock, valued at approximately $90,000. Renaissance Technologies LLC owned 0.53% of InVivo Therapeutics at the end of the most recent reporting period. 0.48% of the stock is currently owned by hedge funds and other institutional investors.
InVivo Therapeutics stock traded down $0.04 during mid-day trading on Tuesday, reaching $0.73. 666,006 shares of the company’s stock were exchanged, compared to its average volume of 4,068,983. The business’s fifty day simple moving average is $0.93 and its 200 day simple moving average is $0.93. InVivo Therapeutics has a one year low of $0.50 and a one year high of $2.55.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.
Further Reading: What is the Fibonacci sequence?
Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.